Hitoshi Kiyoi

List of Publications by Year
in descending order

82 papers	4,482 citations	126907 33 h-index	106344 65 g-index
82 all docs	82 docs citations	82 times ranked	5981 citing authors

#	Article	IF	Citations
1	Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory Bâ€cell precursor acute lymphoblastic leukemia. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 311-318.	1.1	6
2	Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations. Blood, 2022, 139, 1850-1862.	1.4	28
3	Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells. International Journal of Hematology, 2022, 115, 371.	1.6	2
4	Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells. Nature Communications, 2022, 13, 1624.	12.8	11
5	Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy. International Journal of Hematology, 2022, 116, 89-101.	1.6	2
6	Frequent genetic alterations in immune checkpointâ€“related genes in intravascular large B-cell lymphoma. Blood, 2021, 137, 1491-1502.	1.4	49
7	Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma. Oncogene, 2021, 40, 3989-4003.	5.9	22
8	Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells. Journal of Immunology, 2021, 206, 2862-2874.	0.8	4
9	Current progress and future perspectives of research on intravascular large Bâ€cell lymphoma. Cancer Science, 2021, 112, 3953-3961.	3.9	14
10	Bursitis, Bacteremia, and Disseminated Infection of <i>Mycobacteroides</i> (<i>Mycobacterium</i>) <i>abscessus</i> subsp. <i>massiliense</i>. Internal Medicine, 2021, 60, 3041-3045.	0.7	3
11	Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival. Molecular Therapy, 2021, 29, 2677-2690.	8.2	17
12	FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Science, 2020, 111, 312-322.	3.9	124
13	Artificial T Cell Adaptor Molecule-Transduced TCR-T Cells Demonstrated Improved Proliferation Only When Transduced in a Higher Intensity. Molecular Therapy - Oncolytics, 2020, 18, 613-622.	4.4	6
14	Clinical utility of target captureâ€based panel sequencing in hematological malignancies: A multicenter feasibility study. Cancer Science, 2020, 111, 3367-3378.	3.9	11
15	Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Advances, 2020, 4, 66-75.	5.2	63
16	Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3 â€internal tandem duplication AML: The JALSG AML209â€FLT3â€SCT study. Cancer Science, 2020, 111, 2472-2481.	3.9	3
17	JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML). International Journal of Hematology, 2020, 111, 595-613.	1.6	12
18	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 593-602.	10.7	55

#	Article	IF	Citations
19	Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. Cancer Science, 2020, 111, 1314-1323.	3.9	19
20	Pyruvate secreted from patientâ€derived cancerâ€associated fibroblasts supports survival of primary lymphoma cells. Cancer Science, 2019, 110, 269-278.	3.9	41
21	Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. Annals of Hematology, 2019, 98, 83-91.	1.8	19
22	Introduction of Genetically Modified CD3Î¶ Improves Proliferation and Persistence of Antigen-Specific CTLs. Cancer Immunology Research, 2018, 6, 733-744.	3.4	14
23	Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leukemia Research, 2018, 66, 20-27.	0.8	44
24	Mutation analysis of therapy-related myeloid neoplasms. Cancer Genetics, 2018, 222-223, 38-45.	0.4	11
25	A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. Blood, 2018, 131, 426-438.	1.4	104
26	Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11711-E11720.	7.1	192
27	Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome. Leukemia Research, 2017, 63, 90-97.	0.8	24
28	Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism. Oncotarget, 2017, 8, 13085-13098.	1.8	16
29	FLT3 Inhibitors. , 2017, , 167-179.		0
30	Peripheral blood cellâ€free <scp>DNA</scp> is an alternative tumor <scp>DNA</scp> source reflecting disease status in myelodysplastic syndromes. Cancer Science, 2016, 107, 1329-1337.	3.9	20
31	<scp>SPIB</scp> is a novel prognostic factor in diffuse large Bâ€cell lymphoma that mediates apoptosis via the <scp>PI</scp>3Kâ€<scp>AKT</scp> pathway. Cancer Science, 2016, 107, 1270-1280.	3.9	22
32	A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration. Cancer Immunology Research, 2016, 4, 658-668.	3.4	135
33	Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nature Genetics, 2016, 48, 569-574.	21.4	198
34	Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget, 2016, 7, 47018-47032.	1.8	34
35	Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Scientific Reports, 2015, 5, 13054.	3.3	22
36	Target Antigen Density Governs the Efficacy of Antiâ€“CD20-CD28-CD3 Î¶ Chimeric Antigen Receptorâ€“Modified Effector CD8+ T Cells. Journal of Immunology, 2015, 194, 911-920.	0.8	228

#	Article	IF	Citations
37	FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION. Nagoya Journal of Medical Science, 2015, 77, 7-17.	0.3	37
38	Guest editorial: efficacy of and resistance to molecularly targeted therapy for myeloid malignancies. International Journal of Hematology, 2013, 97, 681-682.	1.6	0
39	GATA2 zinc finger 2 mutation found in acute myeloid leukemia impairs myeloid differentiation. Leukemia Research Reports, 2013, 2, 21-25.	0.4	13
40	Gene mutations of acute myeloid leukemia in the genome era. International Journal of Hematology, 2013, 97, 165-174.	1.6	56
41	CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. Experimental Hematology, 2012, 40, 724-737.e2.	0.4	18
42	Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome. Biochemical and Biophysical Research Communications, 2012, 419, 662-669.	2.1	25
43	Y654 of Î²â€catenin is essential for FLT3/ITDâ€related tyrosine phosphorylation and nuclear localization of Î²â€catenin. European Journal of Haematology, 2012, 88, 314-320.	2.2	25
44	A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood, 2011, 117, 2366-2372.	1.4	155
45	Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood, 2011, 117, 2358-2365.	1.4	218
46	FLT3/â€ŠITD regulates leukaemia cell adhesion through Î±4Î²1 integrin and Pyk2 signalling. European Journal of Haematology, 2011, 86, 191-198.	2.2	16
47	A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. International Journal of Hematology, 2011, 93, 237-242.	1.6	12
48	Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia. Leukemia Research, 2011, 35, 685-688.	0.8	8
49	Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia. International Journal of Hematology, 2010, 92, 624-633.	1.6	8
50	Trough plasma concentration of imatinib reflects BCRâ€“ABL kinase inhibitory activity and clinical response in chronicâ€phase chronic myeloid leukemia: A report from the BINGO study. Cancer Science, 2010, 101, 2186-2192.	3.9	49
51	Clinical Features and Outcomes of Elderly Patients with Acute Promyelocytic Leukemia (APL) - the Japan Adult Leukemia Study Group APL97 Study.. Blood, 2010, 116, 1077-1077.	1.4	1
52	Biomarkers In Cell Death of Imatinib-Resistant Ph-Leukemia Cells During Treatment with mTOR Inhibitor, Everolimus. Blood, 2010, 116, 3988-3988.	1.4	0
53	Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib In Ph-Leukemia Quiescent Cells.. Blood, 2010, 116, 1579-1579.	1.4	0
54	Rapid Reduction of Chronic Myeloid Leukemia Stem Cells After Treatment with Second-Generation BCR-ABL Kinase Inhibitors, Dasatinib and Nilotinib. Blood, 2010, 116, 4457-4457.	1.4	0

#	Article	IF	Citations
55	Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia. European Journal of Haematology, 2009, 83, 90-98.	2.2	41
56	Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood, 2009, 113, 4885-4893.	1.4	217
57	KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood, 2009, 114, 1607-1617.	1.4	108
58	Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib in Ph-Leukemia Quiescent or T315I-Mutated Cells.. Blood, 2009, 114, 3277-3277.	1.4	1
59	Donor cell leukemia after allogeneic peripheral blood stem cell transplantation: a case report and literature review. International Journal of Hematology, 2008, 88, 111-115.	1.6	14
60	Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5472-5477.	2.2	10
61	Treatment with Hsp90 Inhibitor, 17-AAG Overcomes Resistance to Small Molecule FLT3-Inhibitors in FLT3/ITD-Positive Leukemia Cells Harboring N676K-Mutation.. Blood, 2008, 112, 1619-1619.	1.4	0
62	A Novel FLT3 Inhibitor FI-700 Selectively Suppresses the Growth of Leukemia Cells with FLT3 Mutations. Clinical Cancer Research, 2007, 13, 4575-4582.	7.0	32
63	Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy. International Journal of Hematology, 2007, 86, 49-57.	1.6	43
64	<I>FLT3</I> Mutations in Acute Myeloid Leukemia. , 2006, 125, 189-198.		12
65	Establishment of a Stroma-Dependent Human Acute Myelomonocytic Leukemia Cell Line, NAMO-2, with FLT3 Tandem Duplication. International Journal of Hematology, 2006, 84, 328-336.	1.6	6
66	Biology, Clinical Relevance, and Molecularly Targeted Therapy in Acute Leukemia with FLT3 Mutation. International Journal of Hematology, 2006, 83, 301-308.	1.6	60
67	Prognostic Analysis of Aberrant Somatic Hypermutation of RhoH in Diffuse Large B Cell Lymphoma.. Blood, 2006, 108, 2041-2041.	1.4	4
68	Clinical Significance of FLT3 in Leukemia. International Journal of Hematology, 2005, 82, 85-92.	1.6	61
69	Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood, 2005, 106, 2854-2861.	1.4	247
70	Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood, 2004, 103, 1901-1908.	1.4	232
71	Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood, 2003, 102, 2969-2975.	1.4	80
72	Rapid Screening of Leukemia Fusion Transcripts in Acute Leukemia by Real-time PCR. Leukemia and Lymphoma, 2002, 43, 2291-2299.	1.3	43

#	Article	IF	Citations
73	FLT3 in Human Hematologic Malignancies. Leukemia and Lymphoma, 2002, 43, 1541-1547.	1.3	64
74	Successful Treatment with Imatinib Mesylate of a CML Patient in Megakaryoblastic Crisis with Severe Fibrosis. International Journal of Hematology, 2002, 76, 349-353.	1.6	5
75	Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene, 2002, 21, 2555-2563.	5.9	257
76	FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. Cancer Chemotherapy and Pharmacology, 2001, 48, S27-S30.	2.3	34
77	Immunoglobulin variable region structure and B-Cell malignancies. International Journal of Hematology, 2001, 73, 47-53.	1.6	5
78	Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene, 2000, 19, 624-631.	5.9	505
79	Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. British Journal of Haematology, 1999, 104, 659-664.	2.5	101
80	Analysis of the joining sequences of the t(15;17) translocation in human acute promyelocytic leukemia: Sequence non-specific recombination between thepml andrara genes within identical short stretches. Genes Chromosomes and Cancer, 1995, 12, 37-44.	2.8	35
81	Clonal Analysis of Multiple Point Mutations in the N-rasGene in Patients with Acute Myeloid Leukemia. Japanese Journal of Cancer Research, 1993, 84, 379-387.	1.7	38
82	Minimal residual disease status in pre-B acute lymphoblastic leukemia patients after chemotherapy and bone marrow transplantation: Assessment of the anti-leukemic effects of chemotherapy and BMT. Leukemia Research, 1993, 17, 677-684.	0.8	11